Bristol-Myers Squibb Company

New York Stock Exchange
Back to all articles
Somewhat Bullish +50

Bristol Myers Squibb Q1 Earnings Call Highlights

AI-generated analysis

📈 Bristol Myers Squibb reported first-quarter total revenue of approximately $11.5 billion, representing a 1% year-over-year increase.

🚀 Growth portfolio revenue reached $6.2 billion, up 9% as new products drove expansion in the business.

💊 Breyanzi sales surged 53%, while Camzyos revenue nearly doubled to $314 million amid strong global demand.

⬇️ Opdivo revenue declined 8% to $2.1 billion due to a temporary U.S. wholesaler inventory drawdown.

💉 Eliquis revenue rose 13% to $4.1 billion despite a price reduction and expected inventory normalization in Q2.

🔬 The FDA accepted the iberdomide application for multiple myeloma with priority review, targeting an August 17 decision.

🧬 Positive interim data were reported for mezigdomide showing meaningful improvement in progression-free survival.

⚖️ Gross margin declined by 280 basis points to 70.3% primarily due to product mix and lower collections from price reductions.

💰 The company ended the quarter with $11 billion in cash and equivalents while generating $1.1 billion in operating cash flow.

📉 Diluted EPS came in at $1.58, which included a net charge related to in-process R&D and licensing income.

🎯 Management reaffirmed full-year 2026 guidance and noted results are trending toward the upper end of established ranges.

💸 The company is pursuing approximately $2 billion in productivity savings by the end of 2027 through strategic initiatives.

📊 Opdualag continued to post double-digit growth, while Sotyktu increased 20% globally following a new approval.

🔗 Additional revenue came from Qvantig ($163M), Cobenfy ($56M), and Reblozyl (which grew 15%).

👨‍💼 CEO Chris Boerner emphasized disciplined execution and improving the company's "say-do ratio" across operations.

🗓️ Late 2026 is identified as a key period for multiple pivotal readouts including milvexian and new ADC data.

Bullish Signals
  • Bristol Myers Squibb delivered solid Q1 results with total revenue of approximately $11.5 billion, marking a 1% year-over-year increase.
  • The growth portfolio increased by 9% to $6.2 billion, demonstrating strong momentum in high-potential product lines.
  • Breyanzi revenue grew 53%, attributed to its best-in-class profile and demand across approved indications in the U.S. and international markets.
  • Camzyos revenue nearly doubled to $314 million, driven by continued global demand for the heart condition treatment.
  • Eliquis revenue increased 13% to approximately $4.1 billion, reflecting strong underlying demand despite recent price reductions.
  • Reblozyl grew 15%, showing continued uptake in first- and second-line treatments for MDS-associated anemia.
  • Sotyktu achieved a 20% global growth rate following its recent approval in psoriatic arthritis, with positive potential in lupus and Sjögren's disease pipelines.
  • Opdualag posted another quarter of double-digit growth, reinforced by global demand and its status as the standard of care in first-line melanoma treatment.
  • The company secured major regulatory milestones, including FDA acceptance of iberdomide for multiple myeloma with breakthrough therapy designation and a PDUFA date of Aug. 17.
  • Management highlighted positive phase III interim data for mezigdomide, which demonstrated meaningful improvement in progression-free survival.
  • Bristol Myers Squibb reaffirmed its full-year 2026 guidance, tracking toward the upper end of established ranges, signaling management confidence.
  • The company ended March with a robust $11 billion in cash equivalents and marketable securities while maintaining disciplined capital allocation.
Risk Factors
  • Opdivo revenue declined 8% to $2.1 billion, driven by a U.S. wholesaler inventory drawdown with levels at the low end of the typical range.
  • Eliquis collections were negatively impacted by a U.S. price reduction implemented at the start of the year and increased generic entry across several other brands.
  • Gross margins contracted 280 basis points to 70.3%, primarily due to product mix shifts rather than operational efficiency gains.
  • Operating expenses rose slightly above the prior-year period at $3.9 billion, partly due to incremental investments in new drug candidates.
  • The company recorded a net $0.03 per-share charge related to in-process R&D and licensing income which impacted diluted EPS of $1.58.
  • Cash collections were down approximately $1.2 billion quarter-over-quarter tied to the Eliquis list price reductions, creating near-term headwinds for cash flow.
  • Management reaffirmed full-year 2026 guidance while pursuing productivity savings, indicating ongoing pressure to manage costs and margins amidst growth investments.
Full Analysis
Bristol Myers Squibb reported solid first-quarter results with total revenue of approximately $11.5 billion, representing a 1% year-over-year increase, while its growth portfolio expanded by 9% to reach $6.2 billion. Key performers included Breyanzi, which grew 53%, and Camzyos, whose revenue nearly doubled to $314 million driven by global demand. However, Opdivo revenue decreased 8% to about $2.1 billion due to a U.S. wholesaler inventory drawdown, while Eliquis revenue rose 13% to $4.1 billion despite a U.S. price reduction that impacted collections. Other notable growth came from Reblozyl (up 15%), Sotyktu (up 20% globally), and Cobenfy ($56 million in revenue). Gross margin declined by 280 basis points to 70.3% primarily due to product mix, while diluted EPS stood at $1.58, which included a net $0.03 per-share charge related to in-process R&D. The company ended March with approximately $11 billion in cash and marketable securities, generating roughly $1.1 billion in operating cash flow, though this was affected by about $1.2 billion in lower net cash collections from Eliquis price reductions. Chief Executive Officer Chris Boerner emphasized improved execution, stating the company is delivering a solid Q1 and maintaining shareholder-friendly capital allocation, while CFO David Elkins noted that results are trending toward the upper end of full-year 2026 guidance. The pipeline remains a strategic focus with multiple pivotal readouts expected in late 2026 for milvexian, Cobenfy, admilparant, and iberdomide. The FDA accepted iberdomide for relapsed/refractory multiple myeloma with breakthrough therapy designation and priority review, setting a PDUFA date of August 17. Additionally, the company reported positive interim data for mezigdomide from the SUCCESSOR-2 study, showing meaningful improvement in progression-free survival, and shared positive top-line results for the antibody-drug conjugate iza-bren in a China study treating triple-negative breast cancer. The company is also pursuing $2 billion in productivity savings by end-2027 while remaining selective on business development initiatives.